Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.97K
+1.44%+10.42%+24.49%-1.72% 191B
+1.25%-0.51%-24.24%+24.46% 143B
+1.75%+10.74%-2.62%-17.53% 139B
+0.07%-2.34%-57.71%-17.33% 65.74B
+1.18%+3.91%+17.67%+1.44% 52.27B
-0.52%-0.03%-26.94%-32.29% 43.55B
+0.37%+7.04%+13.89%+14.90% 38.41B
-0.66%+5.34%+5.49%+44.15% 36.76B
+1.26%+6.77%-12.16%-15.48% 29.91B
Average +0.61%+4.45%-6.90%+0.07% 82.17B
Weighted average by Cap. +1.04%+5.19%-3.84%+0.01%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
7
  1. Stock Market
  2. Stocks
  3. SCIE Stock